TimesSquare Capital Management LLC Has $16.49 Million Stock Position in CG Oncology, Inc. (NASDAQ:CGON)

TimesSquare Capital Management LLC lifted its stake in shares of CG Oncology, Inc. (NASDAQ:CGON) by 27.4% in the 3rd quarter, Holdings Channel reports. The fund owned 437,069 shares of the company’s stock after acquiring an additional 94,010 shares during the quarter. TimesSquare Capital Management LLC’s holdings in CG Oncology were worth $16,491,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in CGON. Decheng Capital LLC bought a new position in CG Oncology during the 1st quarter worth about $239,642,000. Vanguard Group Inc. acquired a new stake in CG Oncology in the 1st quarter valued at approximately $97,678,000. BVF Inc. IL bought a new stake in CG Oncology in the 1st quarter valued at approximately $82,716,000. Yu Fan acquired a new position in CG Oncology during the 2nd quarter worth approximately $49,828,000. Finally, Janus Henderson Group PLC bought a new position in shares of CG Oncology during the 1st quarter worth approximately $66,757,000. 26.56% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, Director Hong Fang Song sold 650,455 shares of the company’s stock in a transaction dated Thursday, August 29th. The shares were sold at an average price of $35.36, for a total transaction of $23,000,088.80. Following the transaction, the director now owns 586,982 shares in the company, valued at approximately $20,755,683.52. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

CG Oncology Stock Performance

Shares of CG Oncology stock opened at $39.94 on Monday. The stock’s 50-day moving average is $36.78 and its 200 day moving average is $34.80. CG Oncology, Inc. has a one year low of $25.77 and a one year high of $50.23.

CG Oncology (NASDAQ:CGON) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($0.28) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.42) by $0.14. The business had revenue of $0.11 million for the quarter. Analysts expect that CG Oncology, Inc. will post -1.45 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on CGON. Roth Capital raised shares of CG Oncology to a “strong-buy” rating in a research report on Tuesday, August 27th. Bank of America reaffirmed a “buy” rating and issued a $65.00 price objective on shares of CG Oncology in a research note on Tuesday, October 8th. UBS Group began coverage on shares of CG Oncology in a research note on Thursday, October 24th. They issued a “buy” rating and a $60.00 price objective on the stock. Royal Bank of Canada initiated coverage on CG Oncology in a research report on Monday, September 23rd. They set an “outperform” rating and a $66.00 target price for the company. Finally, HC Wainwright reiterated a “buy” rating and issued a $75.00 price target on shares of CG Oncology in a research report on Tuesday, September 17th. Eight equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, CG Oncology has a consensus rating of “Buy” and an average target price of $63.88.

CG Oncology Profile

CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.